Truqap is often a kinase inhibitor that works by blocking pathways that aid the most cancers cells survive and mature, so lessens cancer advancement. Truqap is from a class of medicines known as an AKT inhibitor. Truqap acquired FDA acceptance on November 17, 2023, after positive benefits from the C